The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10084 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin

Not Open Access | Unconventional secretory pathway activation restores hair cell mechanotransduction in an USH3A model

June 14, 2019 - 18:14 -- NOT Open Access
Author(s): 
Suhasini R. Gopal, Yvonne T. Lee, Ruben Stepanyan, Brian M. McDermott Jr., and Kumar N. Alagramam
Reference: 
PNAS May 28, 2019 116 (22) 11000-11009

The pathogenic variant c.144T>G (p.N48K) in the clarin1 gene (CLRN1) results in progressive loss of vision and hearing in Usher syndrome IIIA (USH3A) patients.

NOT Open Access | Combination of artemisinin-based natural compounds from Artemisia annua L. for the treatment of malaria: Pharmacodynamic and pharmacokinetic studies

July 6, 2018 - 14:27 -- NOT Open Access
Author(s): 
Jing Li, Chao Zhang, Muxin Gong and Manyuan Wang
Reference: 
Phytotherapy Research banner Volume32, Issue7 July 2018 Pages 1415-1420

Currently, the most effective antimalarial is artemisinin, which is extracted from the leaves of medicinal herb Artemisia annua L. (A. annua).

Medical Treatment: 

An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia

August 15, 2017 - 16:18 -- Open Access
Author(s): 
Leang R, Khu N, Mukaka M, Debackere M, Tripura R, Kheang S, Chy S, Kak N, Buchy P, Tarantola A, Menard D, Roca-Felterer A, Fairhurst R, Kheng S, Muth S, Ngak S, Dondorp A, White N, Taylor W
Reference: 
BMC Medicine 2016, 14 :171 (27 October 2016)

In 2012, the World Health Organization recommended the addition of single low-dose primaquine (SLDPQ, 0.25 mg base/kg body weight) to artemisinin combination therapies to block the transmission of Plasmodium falciparum without testing for glucose-6-phosphate dehydrogenase deficiency. 

Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013)

August 15, 2017 - 14:40 -- Open Access
Author(s): 
Myat Htut Nyunt, Myat Thu Soe, Hla Win Myint, Htet Wai Oo, Moe Moe Aye, Soe Soe Han, Ni Ni Zaw, Cho Cho, Phyo Zaw Aung, Khin Thiri Kyaw, Thin Thin Aye, Naychi Aung San, Leonard Ortega, Krongthong Thimasarn, Maria Dorina G. Bustos, Sherwin Galit…
Reference: 
Malaria Journal 2017 16:333, 14 August 2017

Apart from k13, pfarps10, pffd and pfmdr2 are also useful for molecular surveillance of artemisinin resistance especially where k13 mutation has not been reported.

Artemisinin combination therapy mass drug administration in a setting of low malaria endemicity: programmatic coverage and adherence during an observational study in Zanzibar

August 15, 2017 - 14:38 -- Open Access
Author(s): 
Abdullah S. Ali, Narjis G. Thawer, Bakar Khatib, Haji H. Amier, Joseph Shija, Mwinyi Msellem, Abdul-wahid Al-mafazy, Issa A. Garimo, Humphrey Mkali, Mahdi M. Ramsan, Jessica M. Kafuko, Lynn A. Paxton, Richard Reithinger and Jeremiah M. Ngondi
Reference: 
Malaria Journal 2017 16:332, 14 August 2017

Mass drug administration for malaria was well accepted by communities at high risk of malaria in Zanzibar, with high participation and completion rates.

Not Open Access : Clinical and non-clinical safety of artemisinin derivatives in pregnancy.

August 29, 2016 - 15:15 -- NOT Open Access
Author(s): 
Gomes C, Boareto AC, Dalsenter PR
Reference: 
Reprod Toxicol. 2016 Aug 6;65:194-203.

In this review we aimed to assess the results of non-clinical and clinical studies with artemisinin derivatives, their mechanisms of embryotoxicity and discuss the safety of their use during pregnancy.

Organization: 

Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai–Myanmar Border (2003–2013): The Role of Parasite Genetic Factors

August 26, 2016 - 15:19 -- Open Access
Author(s): 
Aung Pyae Phyo, Elizabeth A. Ashley, Francois Nosten, et al.
Reference: 
Clin Infect Dis. (2016) 63 (6): 784-791

Between 2003 and 2013, we studied the efficacy of MAS3 in 1005 patients with uncomplicated P. falciparum malaria in relation to molecular markers of resistance.

Country: 

Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data

June 8, 2016 - 15:49 -- Open Access
Author(s): 
WWARN Gametocyte Study Group
Reference: 
BMC Medicine 2016, 14:79 (24 May 2016)

All relevant studies were identified through a systematic review of PubMed. Risk of bias was evaluated based on study design, methodology, and missing data.

Degradation of Artemisinin-Based Combination Therapies Under Tropical Conditions

May 17, 2016 - 15:47 -- Open Access
Author(s): 
Zoe Hall, Elizabeth Louise Allan, Donelly Andrew van Schalkwyk, Albert van Wyk, and Harparkash Kaur
Reference: 
Am J Trop Med Hyg 2016 94:993-1001

Using this developed methodology, it was found that a quarter of ACTs purchased in Enugu, Nigeria (concurrent study), that would have been classified as substandard, were in fact degraded. Presence of degradation products together with evidence of insufficient APIs can be used to classify drugs as degraded.

Cellular engineering of Artemisia annua and Artemisia dubia with the rol ABC genes for enhanced production of potent anti-malarial drug artemisinin

May 6, 2016 - 17:55 -- Open Access
Author(s): 
Bushra Hafeez Kiani, John Suberu and Bushra Mirza
Reference: 
Malaria Journal 2016 15:252, 4 May 2016

Transformation of Artemisia sp. with rol ABC genes can lead to the increased production of artemisinin, which will help to meet the increasing demand of artemisinin because of its diverse pharmacological and anti-malarial importance.

Pages

Subscribe to RSS - artemisinin